Navigation Links
FDA Approval of Ryanodex® Marks Milestone for Lyotropic Therapeutics
Date:8/6/2014

Richmond, Virginia (PRWEB) August 06, 2014

Lyotropic Therapeutics (Ashland, Virginia) today announced that its license partner, Eagle Pharmaceuticals, has received marketing approval by the U.S. Food and Drug Administration (FDA) for RYANODEX® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. Ryanodex was developed and patented by Lyotropic Therapeutics and is licensed exclusively to Eagle Pharmaceuticals.

About Malignant Hyperthermia
MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. Once triggered, a rapidly progressing reaction involving sustained muscle contraction occurs with catastrophic consequences. Essential to the successful treatment of MH is the rapid institution of dantrolene sodium therapy and control of associated symptoms. Until now, dantrolene sodium preparation entailed a time-consuming reconstitution process and required several people for its preparation, a process that can take 15 to 20 minutes to mix, reconstitute and administer. Lyotropic Therapeutics developed Ryanodex to save critical time in preparation and administration of dantrolene sodium. Ryanodex can be prepared and administered in less than one minute by a single healthcare practitioner.

"Rapid administration of dantrolene sodium has long been recognized as key to reversal of MH. FDA approval of Ryanodex marks the availability of a major advance in the clinician’s ability to quickly prepare and deliver dantrolene sodium in the face of a fulminating MH crisis,” said Benjamin Cameransi, Jr., M.D., D.A.B.A., Vice President of Medical Affairs at Lyotropic Therapeutics. “In addition, approval of Ryanodex strongly validates the Company’s strategy of developing clinically significant new drugs backed with sound proof-of-concept data and then seeking a partner well positioned to complete product development and market the product.”

About Lyotropic Therapeutics
Lyotropic Therapeutics, Inc., based in Ashland, Virginia, is a pharmaceutical development company applying its substantial base of drug delivery technologies to develop unique, proprietary products with the goal of offering major therapeutic advances in patient safety and efficacy. The Company’s approach to product development and partnering has resulted in a significant portfolio of development stage injectable products in the field of anesthesia, pain management and critical care.

CONTACT:

for Lyotropic Therapeutics, Inc.

Vince Conklin, CEO
804.412.1030
vconklin(at)lyotropics(dot)com

Benjamin Cameransi, M.D. , D.A.B.A.,
Vice President of Medical Affairs
912.321.9112
bcameransi(at)lyotropics(dot)com
SOURCE Lyotropic Therapeutics, Inc.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12072145.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
2. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
3. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
6. CSafe Global Celebrates Six-Year Anniversary of RKN FAA Approval and Launch of Fleet
7. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
8. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
9. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
10. Humira and Simponi Have Been Prescribed By Significantly More U.S. Gastroenterologists in 2013 than in 2012, Likely Owing to Their Recent Approvals for Ulcerative Colitis
11. Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: ... and commercialization of innovative biopharmaceutical products for companion animals, will ... at 8:30 a.m. ET to discuss financial results from the ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader ... for all SPIE attendees and Park customers on Feb. 27, 2017 ... the San Jose Convention Center. The luncheon will feature a talk on Automated ...
(Date:2/22/2017)... Scientists propose in Nature blocking a molecule ... maybe other lysosomal storage diseases as a possible treatment ... An international research team led by ... investigators from the University of Lübeck in ... study was conducted in mouse models of lysosomal storage ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or ... neurodegenerative diseases, today announced it has issued a scientific white paper entitled “Results ... a series of commentaries from ProMIS’s scientific team offering insight into the Company’s ...
Breaking Biology Technology:
(Date:1/23/2017)... Jan. 23, 2017  The latest mobile market research ... have dropped dramatically. The quarterly average price of a ... $276 in Q4 2016.  There are now 120 sub-$150 ... $116, up from just 28 a year ago at ... to Maxine Most , Acuity Market Intelligence Principal, ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
Breaking Biology News(10 mins):